Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 3,448 matching trials from the live ClinicalTrials.gov search.
Enrolling by invitation Phase 2 Interventional

Tradipitant for Functional Dyspepsia

NCT05653310
Conditions
Functional Dyspepsia
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Xiao Jing (Iris) Wang
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
OTC Deficiency, Ornithine Transcarbamylase Deficiency, OTCD
Interventions
ARCT-810
Biological
Lead sponsor
Arcturus Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chevy Chase, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control

NCT01250210
Conditions
Ovulation Suppression
Interventions
levonorgestrel and ethinyl estradiol
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
11
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more
Conditions
Solid Tumor
Interventions
QN-302
Drug
Lead sponsor
Qualigen Theraputics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Grand Rapids, Michigan + 1 more
Conditions
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Interventions
Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3
Biological
Lead sponsor
T-MAXIMUM Pharmaceutical Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Healthy Adult Subjects
Interventions
ONO-6950
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Miramar, Florida
Conditions
Psoriasis
Interventions
SB414 6%, Vehicle
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Boise, Idaho • Austin, Texas • College Station, Texas + 1 more
Conditions
Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions
Sebelipase alfa (SBC-102)
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Irvine, California
Conditions
Obesity, Elective Surgery
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of LQT-1213 in Healthy Adults

NCT05759962
Conditions
Long QT Syndrome
Interventions
LQT-1213, Placebo
Drug · Other
Lead sponsor
Thryv Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cypress, California
Conditions
Non-Small-Cell Lung Cancer
Interventions
XL999
Drug
Lead sponsor
Symphony Evolution, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Detroit, Michigan + 2 more
Conditions
Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes
Interventions
AZD3632, Posaconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Decatur, Illinois • New York, New York • Chapel Hill, North Carolina + 3 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of RO4995819 in Healthy Elderly Volunteers

NCT01457664
Conditions
Healthy Volunteer
Interventions
Placebo, RO4995819
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
65 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Miramar, Florida
Conditions
Arthritis, Rheumatoid
Interventions
PD 0360324, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Peoria, Arizona • Daytona Beach, Florida • Port Orange, Florida + 5 more
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO6811135
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Chula Vista, California • Cincinnati, Ohio
Conditions
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Interventions
PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
9
States / cities
Santa Monica, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
Completed Phase 1 Interventional Results available

Valacyclovir in Neonatal Herpes Simplex Virus Disease

NCT04448392
Conditions
Neonatal Herpes Simplex Infection
Interventions
Valacyclovir
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
2 Weeks to 12 Weeks
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Schizophrenia
Interventions
LTX-001 once daily, Placebo, LTX-001 twice daily
Drug
Lead sponsor
Leal Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Alamitos, California • DeLand, Florida + 6 more
Conditions
Epilepsy, Contraception
Interventions
levonorgestrel IUS
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Cancer
Interventions
MGCD265
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
12
States / cities
Duarte, California • Orange, California • San Diego, California + 9 more
Conditions
Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
Interventions
OR2805, Cemiplimab, Docetaxel
Drug
Lead sponsor
OncoResponse, Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Austin, Texas • San Antonio, Texas
Conditions
Glycogen Storage Disease
Interventions
mRNA-3745
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Farmington, Connecticut • Boston, Massachusetts • Durham, North Carolina + 4 more
Conditions
Major Depressive Disorder (MDD)
Interventions
DT-101, Placebo
Drug
Lead sponsor
Draig Therapeutics Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 17 more
Completed Not applicable Interventional Results available

PK/PD Pediatric ADHD Classroom Study

NCT02536105
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate HCl ER tablets 1, Placebo, Methylphenidate HCl ER tablets 2, Methylphenidate HCl ER for suspension
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Las Vegas, Nevada